Aurobindo Pharma Share Price

₹ 1,811.80

+₹17.70 (0.99%)
1D
Last updated 18 Nov, 2026, 11:22 IST
NSE: AUROPHARMA
|
Pharmaceuticals

Aurobindo Pharma Share Price Today

As of 18 Nov 2026, Aurobindo Pharma share price is ₹1,811.80. The stock opened at ₹1,793.60, compared to its previous close of ₹1,794.10. During today's trading session, Aurobindo Pharma share price moved in the range of ₹1,788.70 to ₹1,816.00, with an average price of ₹1,802.35 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,106.00 and a high of ₹1,859.90. On the performance front, Aurobindo Pharma share price has increased by 18.67% over the last six months and is up 45.05% on a year-on-year basis.

Share price over the last 1 day rose from 1796.10 to 1811.80, ranging between 1789.20 and 1815.50.

₹1,788.70
0.99% up today
₹1,816.00
1D LOW
1D HIGH

Aurobindo Pharma Stock Insights

Latest Earning
Op Profit TrendUp by 11.39% QoQ
Latest Earning
Net Profit TrendUp by 8.90% QoQ
Latest Earning
Revenue TrendUp by 10.80% QoQ
Stock Performance
OutperformingBeat Nifty by 4.36 % in last 3 month
Shareholding Pattern
PromoterPromoter decreased stake by 0.01%
Shareholding Pattern
DIIDII decreased stake by 3.36%
Shareholding Pattern
FIIFII increased stake by 6.30%
Aurobindo Pharma stock performance
Open₹1,793.60
High₹1,816.00
Low₹1,788.70
Prev. close₹1,794.10
Aurobindo Pharma trading activity
Volume5,12,253
Average traded price₹1,798.36
Last traded time11:22:38 18 Nov
Last traded quantity33

Circuit
L
H
₹1,614.70
₹1,973.50
52-week
L
H
₹1,106.00
₹1,859.90
Mkt Cap Cr
1,03,145.12

P/E
25.8

P/B
2.61

ROA
6.46%
ROE
10.13%

ROCE
12.76%

Quick Ratio
1.15

EV/EBITDA
12.65

Based on fundamentals, this stock's

Performance: 5 out of 5, Excellent
Performance
Excellent
Aurobindo Pharma outperforming all market indices
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Aurobindo Pharma appears overvalued compared to its peers
Earnings: 5 out of 5, Excellent
Earnings
Excellent
Aurobindo Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,47,943.8440.775.029.61%13.79%18.65%2.3123.61
Divis Laboratories2,94,962.1487.7416.415.31%18.69%23.83%3.558.71
Torrent Pharmaceuticals1,78,390.6284.659.674.7%11.42%11.37%0.7534.13
Laurus Labs1,19,789.9294.8920.8611.58%22.11%20.91%0.6850.63
Zydus Lifesciences1,19,969.7927.574.267.63%15.1%14.86%0.9115.91
Dr. Reddy's Laboratories1,15,852.1741.772.974.79%7.21%8.58%1.3519.44
Cipla1,12,619.6039.473.186.6%8.18%10.8%2.521.23
Mankind Pharma1,08,424.3447.96.177.82%12.76%14.68%0.7426.43
Lupin90,201.0517.113.7213.08%21.65%24.54%1.4210.13
Glenmark Pharma74,194.0450.836.586.78%18.07%19.86%1.2326.95

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Aurobindo Pharma Company Background

ISIN
INE406A01037
Sector Market Cap
₹ 103,145.12 Cr

Founded in 1986 by PV Ramprasad Reddy and K Nityananda Reddy, Aurobindo Pharma is one the largest pharmaceutical companies in India. Its operations began in 1988 with a single unit producing semi-synthetic penicillin (SSP) in Puducherry. The company went public in 1992 and was listed on the stock exchanges in 1995.

The market capitalisation of Aurobindo Pharma Limited is over ₹63,800 crore as of December 28, 2023. Aurobindo Pharma share price has gained over 14% in three years.

Business operations

Aurobindo Pharma specialises in producing semi-synthetic penicillin and has a strong presence in various essential medical areas such as cephalosporins, antivirals, cardiovascular and gastroenterology. It is the leading provider of semi-synthetic penicillin medications. The company's product range covers formulations like those for cardiovascular, gastroenterology, antiretrovirals and anti-infectives.

Notable formulations include trandolapril, captopril, and benazepril hydrochloride, among others. It also manufactures active pharmaceutical ingredients and organic intermediates like desmethyl azithromycin, methenamine and benzimidazole.

Aurobindo Pharma operates 11 units for APIs/intermediates and 15 units (10 in India, three in the USA, one in Brazil and one in Portugal) for formulations, strategically designed to cater to both established and emerging market needs.

In the United States, Aurobindo Pharma operates across oral medications, injectables, over-the-counter and branded oncology segments. It has submitted 774 ANDAs (abbreviated new drug applications) and received 565 final approvals as of March 31, 2023.

In Europe, Aurobindo Pharma has established its presence in 10 countries with fully equipped pharmacies, hospitals, and sales infrastructure for tenders.

Its business model heavily relies on its input. A total of ₹1,411.5 crore was allocated towards research and development (R&D). This initiative led to the submission of 774 Abbreviated New Drug Applications (ANDAs), 276 Drug Master Files (DMFs) and 813 filed patent applications. The company filed 4,359 formulation dossiers and 3,718 API (Active Pharmaceutical Ingredient) product submissions in various markets outside the USA.

As an integrated pharmaceutical company, Aurobindo Pharma ranks among India's top pharmaceutical firms in terms of combined revenues. Exporting to over 150 countries globally, approximately 90% of its revenue comes from international ventures, serving esteemed multinational clientele.

Aurobindo Pharma’s facilities have approvals from major regulatory bodies across the world such as USFDA, EU GMP, UK MHRA, Health Canada, WHO and Brazil ANVISA.

Aurobindo Pharma operates five research centres spanning 16,000 square meters, along with two additional R&D centres in the USA. The company has a team of over 1,560 in-house scientists and analysts for product development.

Aurobindo Pharma Financial Highlights

  • Revenue: Aurobindo Pharma reported revenue of ₹34,145.17 crore in FY26 vs ₹32,345.58 crore in FY25. It showed an increase of 5.56% on a yearly basis.
  • Operating Profit: Aurobindo Pharma reported an operating profit of ₹5,111.85 crore in FY26 vs ₹5,066.29 crore in FY25. It showed an increase of 0.90% on a year-on-year basis.
  • Net Profit: Aurobindo Pharma reported a net profit of ₹3,502.97 crore in FY26 vs ₹3,483.57 crore in FY25. It showed an increase of 0.56% on a yearly basis.

Aurobindo Pharma Quarterly Result Highlights

  • Aurobindo Pharma reported revenue of ₹10,431.51 crore in Sep 2026, compared with ₹9,414.58 crore in Jun 2026, representing an increase of 10.80% on a quarter-on-quarter (QoQ) basis.
  • Aurobindo Pharma reported an operating profit of ₹1,687.67 crore in Sep 2026, compared with ₹1,515.09 crore in Jun 2026, representing an increase of 11.39% on a quarter-on-quarter (QoQ) basis.
  • Aurobindo Pharma reported a profit of ₹1,123.84 crore in Sep 2026, compared with ₹1,032.03 crore in Jun 2026, reflecting an increase of 8.90% on a QoQ basis.
  • The earnings per share (EPS) of Aurobindo Pharma stood at ₹60.34 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
51.88%
FII
17.41%
Other DII
8.11%
Retail and other
6.29%
Mutual funds
16.31%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202513.94%
Mar 202615.24%
Jun 202616.38%
Sep 202617.41%

Aurobindo Pharma Investment Returns

1 day
+0.01%

1 week
-3.30%

1 month
+7.63%

1 year
+45.05%

3 years
+78.10%

5 years
+169.16%

Aurobindo Pharma Share Price History

Aurobindo Pharma share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
17 Nov 26
₹1,792.10 / ₹1,794.10
+0.01%
16 Nov 26
₹1,830.90 / ₹1,794.00
-1.60%
13 Nov 26
₹1,800.10 / ₹1,823.20
+0.89%
12 Nov 26
₹1,813.10 / ₹1,807.20
-1.11%
Show more

Aurobindo Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹33,653.08₹31,723.73₹29,001.87₹24,855.38
Other Income₹492.09₹621.85₹557.38₹290.59
Total Revenue₹34,145.17₹32,345.58₹29,559.25₹25,145.97
Total Expenses₹28,969.51₹27,247.60₹24,970.24₹22,521.80
Profit Before Tax₹5,111.85₹5,066.29₹4,379.99₹2,612.50
Tax₹1,608.88₹1,582.72₹1,211.02₹684.85
Profit After Tax₹3,502.97₹3,483.57₹3,168.97₹1,927.65
EPS - Basic₹60.34₹59.81₹54.16₹32.90
EPS - Diluted₹60.34₹59.81₹54.16₹32.90

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹5,111.85₹5,066.29₹4,379.99₹2,612.50
Income before WC changes₹7,194.47₹6,900.45₹5,876.23₹4,198.97
Change in Assets-₹2,935.17-₹1,597.91-₹2,410.44-₹1,933.13
Change in Liabilities₹3,099.10₹353.43₹735.37₹838.15
Change in WC₹163.93-₹1,244.48-₹1,675.07-₹1,094.98
Cash flow from Operations₹5,526.37₹3,924.62₹2,434.52₹2,386.75
Cash flow from Investing-₹3,458.61-₹1,875.80-₹4,255.95-₹3,977.75
Cash flow from Financing-₹1,269.15₹119.78₹800.42₹1,814.41
Total Cash Flow₹798.61₹2,168.60-₹1,021.01₹223.41
Cash (Start of the year)₹5,563.79₹3,385.43₹4,392.27₹4,162.51
Cash (End of the year)₹7,191.40₹5,563.79₹3,385.43₹4,392.27

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹25,793.40₹22,622.51₹21,299.59₹18,430.08
Current Assets₹32,708.75₹27,162.46₹23,771.92₹21,459.91
Total Assets₹58,502.15₹49,784.97₹45,071.51₹39,889.99
Current Liabilities₹18,039.01₹14,682.34₹12,199.13₹11,493.78
Net Current Asset₹14,669.74₹12,480.12₹11,572.79₹9,966.13
Non-Current Liabilities₹2,580.33₹2,455.70₹3,021.58₹1,544.36
Equity Capital₹37,882.81₹32,646.93₹29,850.80₹26,851.85
Total Equity & Liabilities₹58,502.15₹49,784.97₹45,071.51₹39,889.99

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹11,171.72₹10,933.30₹10,645.64₹8,457.00
Other Income₹587.53₹328.12₹616.06₹443.92
Total Revenue₹11,759.25₹11,261.42₹11,261.70₹8,900.92
Total Expenses₹8,578.29₹8,902.97₹8,858.78₹7,269.93
Profit Before Tax₹3,163.58₹2,358.45₹2,402.92₹1,630.99
Tax₹748.78₹611.66₹502.82₹388.82
Profit After Tax₹2,414.80₹1,746.79₹1,900.10₹1,242.17
EPS - Basic₹41.58₹29.97₹33.35₹20.94
EPS - Diluted₹41.58₹29.97₹33.35₹20.94

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹3,163.58₹2,358.45₹2,475.41₹1,611.23
Income before WC changes₹3,237.23₹2,642.57₹2,545.02₹1,786.43
Change in Assets₹548.08-₹170.41-₹1,366.10₹251.08
Change in Liabilities-₹84.48-₹157.21₹1,138.06₹79.29
Change in WC₹463.60-₹327.62-₹228.04₹330.37
Cash flow from Operations₹2,933.02₹1,645.79₹1,714.80₹1,816.17
Cash flow from Investing-₹2,024.96-₹2,065.90-₹159.96-₹3,457.62
Cash flow from Financing-₹1,072.35₹616.31-₹1,837.03₹1,719.48
Total Cash Flow-₹164.29₹196.20-₹282.19₹78.03
Cash (Start of the year)₹295.26₹83.32₹357.13₹51.13
Cash (End of the year)₹160.43₹295.26₹83.32₹357.13

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹21,257.50₹19,823.66₹17,914.85₹15,093.82
Current Assets₹8,021.88₹7,689.40₹7,239.13₹9,964.99
Total Assets₹29,279.38₹27,513.06₹25,153.98₹25,058.81
Current Liabilities₹6,299.35₹6,420.50₹5,244.74₹6,678.65
Net Current Asset₹1,722.53₹1,268.90₹1,994.39₹3,286.34
Non-Current Liabilities₹262.34₹558.45₹186.42₹346.13
Equity Capital₹22,717.69₹20,534.11₹19,722.82₹18,034.03
Total Equity & Liabilities₹29,279.38₹27,513.06₹25,153.98₹25,058.81
* All values are in INR Crore
Aurobindo Pharma market depth
Bid quantityBid priceAsk priceAsk quantity
1201811.8181270
11811.71812.117
391811.61812.293
1931811.51812.369
221811.41812.449
Total bid quantity375
Total ask quantity298
Aurobindo Pharma technical summary
Bearish indicators1
Neutral indicators6
Bullish indicators1
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict

RSI (14)
60.38
Neutral

ATR (14)
43.25
Neutral

STOCH(9,6)
60.98
Neutral

STOCH RSI (14)
44.11
Neutral

ADX(9)
45.2
Bearish

UO(9)
59.66
Neutral

ROC(12)
8.08
Bullish

WillR(14)
-26.28
Neutral
Period
Simple value
Exponential vaue

5D
1809.2
1801.97

10D
1799.53
1785.27

20D
1716.93
1749.29

50D
1696.66
1699.24

100D
1646.46
1639.2
Volume trend — traded volume by day
18 Nov5L
17 Nov9L
16 Nov14L
13 Nov11L
12 Nov22L
11 Nov23L
Average14L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Aurobindo Pharma
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Aurobindo Pharma

Fund name
AUM
Quant Mid Cap Fund
9.92%

Quant Manufacturing Fund
9.81%

Quant Large and Mid Cap Fund
7.92%

Aurobindo Pharma Returns Calculator

Ex-date: 11 Nov 2026

Aurobindo Pharma Latest News

6 days ago
Stocks to watch, Nov 12: Bharat Dynamics, HAL, Bajaj Finance, Tata Power, Aurobindo Pharma, IRCTC, Page Industries
1 week ago
Dabur, NBCC India, CONCOR and others: Dividend record dates this week; check full list
1 month ago
Stocks to watch, Oct 1: Auto stocks, Tech Mahindra, NCC, Aurobindo Pharma, Linde India, Mahindra Lifespace, Transrail Lighting
2 months ago
Sun Pharma, Laurus Labs, Mankind Pharma, others drag Nifty Pharma down 1.6%; here’s what investors should know
3 months ago
Dividend, stock split this week: Muthoot Finance, Aurobindo Pharma, Pashupati Cotspin, others in focus
3 months ago
Q3 Results Today: BSE, Zydus Lifesciences, Aurobindo Pharma, Pfizer, GSK, Ramco Cements, PNG, others to post earnings on Feb 9; check list
3 months ago
Sun Pharma, Cipla, other pharma stocks decline as Trump unveils steep tariff plan on generic drugs: Key FAQs answered
4 months ago
Torrent Pharma, Mankind, Cipla, others lift Nifty Pharma 1.8%; why are pharma stocks rising in weak market?
4 months ago
Aurobindo Pharma shares trade lower after US FTC approves $250 million Lannett Co. acquisition move
5 months ago
Stocks to watch, June 5: Rate-sensitives, Lupin, CG Power, Aurobindo Pharma, Hindalco, Ola Electric
Showing news item 1 of 10

Aurobindo Pharma Share Price FAQs












Please be aware that Aurobindo Pharma stock prices are subject to continuous fluctuations due to various factors.